drugset / Trial / NCT04750252
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
NaSingle-groupOpen-labelTreatment
Summary
The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION | Cell therapy | — | — |